What is the relationship between sclerostin and cardiovascular events in hemodialysis patients?
Main Authors: | Yu Zhao, Wenyun Wang, Zhilong Dong |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | Renal Failure |
Online Access: | http://dx.doi.org/10.1080/0886022X.2020.1845733 |
Similar Items
-
Association of sclerostin with cardiovascular events and mortality in dialysis patients
by: Yun Zou, et al.
Published: (2020-01-01) -
Trimethylamine N-Oxide and mortality in hemodialysis patients: like a mystery
by: Yu Zhao, et al.
Published: (2021-01-01) -
Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes
by: Maria Carolina Medeiros, et al.
Published: (2020-01-01) -
Role of sclerostin, fibroblast growth factor-23, and Klotho in hemodialysis patients
by: Azza A I. Elmenyawi, et al.
Published: (2019-01-01) -
Correlation between serum sclerostin level and bone density status in children on regular hemodialysis
by: Manal Abd Elsalam, et al.
Published: (2019-01-01)